Stealth BioTherapeutics Corp to Post FY2023 Earnings of ($0.01) Per Share, Jefferies Financial Group Forecasts (NASDAQ:MITO)

Share on StockTwits

Stealth BioTherapeutics Corp (NASDAQ:MITO) – Equities research analysts at Jefferies Financial Group issued their FY2023 earnings per share estimates for shares of Stealth BioTherapeutics in a report issued on Thursday, August 15th. Jefferies Financial Group analyst M. Raycroft expects that the company will earn ($0.01) per share for the year.

Stealth BioTherapeutics (NASDAQ:MITO) last released its earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.04.

A number of other research analysts have also recently commented on the company. Zacks Investment Research cut Stealth BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 18th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Stealth BioTherapeutics in a research note on Friday, July 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Stealth BioTherapeutics currently has an average rating of “Buy” and an average price target of $24.83.

MITO opened at $10.79 on Monday. The stock has a market cap of $423.51 million and a PE ratio of -7.65. The company has a 50 day moving average price of $12.17. Stealth BioTherapeutics has a 52 week low of $10.70 and a 52 week high of $20.99.

A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new stake in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned about 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 0.73% of the stock is currently owned by institutional investors and hedge funds.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Read More: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EZCORP  Stock Price Down 11.5%
EZCORP Stock Price Down 11.5%
Opera  Stock Price Down 7.5%
Opera Stock Price Down 7.5%
Lexicon Pharmaceuticals  Trading Down 9.2%
Lexicon Pharmaceuticals Trading Down 9.2%
Hi-Crush  Trading Down 6.8%
Hi-Crush Trading Down 6.8%
Spi Energy  Trading Down 12.2%
Spi Energy Trading Down 12.2%
Dynagas LNG Partners  Trading Down 8.3%
Dynagas LNG Partners Trading Down 8.3%


© 2006-2019 Ticker Report